Safety of Bispecific Antibodies in Patients With Autoimmune Disease and Hematologic Malignancies: A Real-World Propensity-Matched Study (ACR Convergence 2026) - Sep 8, 2026 - Abstract #2682; Pres time: Nov 10, 2026; 10:30 AM - 12:30 PM; Location: WB1&2; In Person; "Adults with hematologic malignancies receiving BsAb therapy (teclistamab, elranatamab, blinatumomab, mosunetuzumab, glofitamab, or epcoritamab) were identified...Propensity score matching (1:1) balanced demographics, malignancy type, comorbidities, and prior glucocorticoid, methotrexate, rituximab, and antirheumatic exposures... Pre-existing autoimmune disease was associated with increased infectious complications, opportunistic infections, and critical illness within 90 days of BsAb therapy. Opportunistic infections persisted through 180 days. These findings highlight the need for infectious surveillance and prophylaxis as BsAbs enter rheumatologic practice."
Bispecific • Clinical • Real-world • Real-world evidence • Ankylosing Spondylitis • Autoimmune Hepatitis • Axial Spondyloarthritis • CNS Disorders • Hematological Malignancies • Hepatology • Immunology • Infectious Disease • Inflammatory Arthritis • Multiple Sclerosis • Myasthenia Gravis • Oncology • Psoriatic Arthritis • Rheumatoid Arthritis • Scleroderma • Septic Shock • Seronegative Spondyloarthropathies • Sjogren's Syndrome • Systemic Sclerosis • Vasculitis
|
|
ivan damara1; akhil vatvani2
|